| (Values in U.S. Thousands) | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 | Sep, 2017 |
| Sales | 26,690 | 0 | 0 | 0 | -6,830 |
| Sales Growth | unch | unch | unch | +100.00% | -68.64% |
| Net Income | -37,840 | -33,290 | -11,940 | -2,540 | 13,000 |
| Net Income Growth | -13.67% | -178.81% | -370.08% | -119.54% | +224.19% |
Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.
Eidos Therapeutics Inc (EIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.
Fiscal Year End Date: 12/31